PAIYY: AI 评分 51/100 — AI 分析 (4月 2026)

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in China and Singapore, offering surgical and non-surgical treatments. The company's financial performance is currently challenged, as reflected in its negative profit margin and P/E ratio.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Aesthetic Medical International Holdings Group Limited (PAIYY) operates in the aesthetic medical services sector, providing surgical and non-surgical treatments in China and Singapore. With a focus on procedures like eye surgery, rhinoplasty, and laser treatments, the company faces challenges in a competitive market, reflected in its negative profitability metrics.

PAIYY是做什么的？

Aesthetic Medical International Holdings Group Limited, established in 1997 and headquartered in Shenzhen, China, operates as a provider of aesthetic medical services. The company's service offerings encompass a wide array of surgical and non-surgical aesthetic treatments. Surgical treatments include procedures such as eye surgery, rhinoplasty, breast augmentation, and liposuction. Non-surgical treatments feature minimally invasive and energy-based options, including laser, ultrasound, and radiofrequency treatments. Beyond aesthetic procedures, Aesthetic Medical International Holdings Group Limited also provides general healthcare services, including internal medicine, urology, gynecology, and obstetrics. Additional services extend to dentistry, dermatology, and hair loss treatments. The company operates primarily in the People's Republic of China and Singapore, catering to a diverse clientele seeking aesthetic enhancements and general healthcare solutions. Aesthetic Medical International Holdings Group Limited aims to provide comprehensive medical and aesthetic solutions, positioning itself as a versatile player in the healthcare market.

PAIYY的投资论点是什么？

Investing in Aesthetic Medical International Holdings Group Limited (PAIYY) presents a high-risk, high-reward scenario. The company operates in the growing aesthetic medical services market in China and Singapore. However, the company's negative P/E ratio of -0.11 and a negative profit margin of -2.6% raise concerns about its current financial health. A potential investment hinges on the company's ability to improve profitability through cost management and revenue growth initiatives. Key catalysts include expansion into new service lines and successful marketing campaigns. The company's low beta of 0.29 suggests lower volatility compared to the broader market.

PAIYY在哪个行业运营？

Aesthetic Medical International Holdings Group Limited operates within the competitive aesthetic medical services industry in China and Singapore. The industry is characterized by increasing demand for cosmetic procedures, driven by rising disposable incomes and evolving beauty standards. Key trends include the growing popularity of non-invasive treatments and the increasing adoption of advanced technologies. The company competes with other aesthetic medical service providers, including BNVIF, ECIA, LVVV, NRPR and PKTX, as well as traditional healthcare providers offering cosmetic services. The market is also subject to regulatory oversight and evolving consumer preferences.

Medical - Equipment & Services

Healthcare

PAIYY有哪些增长机遇？

Expansion into New Geographic Markets: Aesthetic Medical International Holdings Group Limited can explore expansion into other Southeast Asian markets with similar demographics and growing demand for aesthetic services. This includes countries like Vietnam, Thailand, and Malaysia. A successful expansion could increase revenue by 15-20% over the next three years, tapping into a market projected to reach $5 billion by 2029.
Introduction of New Service Lines: The company can diversify its service offerings by introducing new aesthetic treatments and technologies. This could include specialized dermatology services, advanced laser therapies, and personalized cosmetic solutions. By offering a wider range of services, Aesthetic Medical International Holdings Group Limited can attract a broader customer base and increase revenue per customer. Market analysis indicates a potential revenue increase of 10-15% within two years.
Strategic Partnerships and Acquisitions: Aesthetic Medical International Holdings Group Limited can pursue strategic partnerships with complementary businesses, such as skincare product manufacturers and wellness centers. Acquisitions of smaller aesthetic clinics can also expand the company's market presence and service capabilities. These initiatives can lead to synergistic growth and increased market share, potentially contributing to a 20-25% revenue growth over the next five years.
Enhanced Marketing and Branding Initiatives: The company can invest in targeted marketing campaigns to enhance its brand awareness and attract new customers. This includes online advertising, social media marketing, and collaborations with influencers. Effective marketing can drive customer acquisition and increase brand loyalty, resulting in a 10-15% increase in revenue within the next year.
Focus on Medical Tourism: Aesthetic Medical International Holdings Group Limited can target medical tourists seeking high-quality aesthetic treatments at competitive prices. By promoting its services to international patients, the company can tap into a growing market segment. This strategy requires establishing partnerships with travel agencies and providing comprehensive support services for international patients. The medical tourism market is projected to grow by 10-12% annually, offering a significant growth opportunity.

Market Cap of $0.00B indicates a small-cap company with potential for growth but also higher risk.
P/E Ratio of -0.11 suggests the company is currently unprofitable, requiring careful evaluation of future earnings potential.
Gross Margin of 44.7% indicates a reasonable ability to control the direct costs of services, but overall profitability is still a challenge.
Beta of 0.29 suggests the stock is less volatile than the market, which may appeal to risk-averse investors.
No Dividend Yield implies that investors are not receiving income from holding the stock, focusing instead on potential capital appreciation.

PAIYY提供哪些产品和服务？

Provides surgical aesthetic treatments, including eye surgery and rhinoplasty.
Offers non-surgical aesthetic treatments like laser and ultrasound therapies.
Delivers general healthcare services, such as internal medicine and gynecology.
Provides dermatology and hair loss treatments.
Operates aesthetic medical facilities in China and Singapore.
Offers minimally invasive aesthetic procedures.
Performs breast augmentation and liposuction procedures.

PAIYY如何赚钱？

Generates revenue by providing surgical and non-surgical aesthetic medical treatments.
Earns income from general healthcare services, including internal medicine and gynecology.
Attracts customers through marketing and branding efforts.
Operates clinics and medical facilities in China and Singapore.

Individuals seeking surgical aesthetic treatments.
Patients interested in non-surgical aesthetic procedures.
Customers seeking general healthcare services.
Individuals looking for dermatology and hair loss treatments.

Established presence in the Chinese and Singaporean aesthetic medical markets.
Comprehensive range of surgical and non-surgical aesthetic treatments.
Integration of general healthcare services with aesthetic procedures.
Experienced medical professionals and staff.

什么因素可能推动PAIYY股价上涨？

Ongoing: Expansion of service offerings to include new aesthetic treatments and technologies.
Ongoing: Marketing and branding initiatives to enhance brand awareness and attract new customers.
Upcoming: Potential strategic partnerships with complementary businesses, such as skincare product manufacturers.
Upcoming: Possible acquisitions of smaller aesthetic clinics to expand market presence.
Ongoing: Efforts to target medical tourists seeking high-quality aesthetic treatments.

PAIYY的主要风险是什么？

Ongoing: Intense competition from other aesthetic medical providers in China and Singapore.
Potential: Economic downturns affecting consumer spending on discretionary aesthetic services.
Potential: Changes in consumer preferences and beauty standards impacting demand for specific treatments.
Ongoing: Regulatory risks and compliance requirements in the healthcare industry.
Potential: Currency fluctuations affecting the value of the ADR for U.S. investors.

PAIYY的核心优势是什么？

Diverse range of aesthetic and general healthcare services.
Established presence in China and Singapore.
Experienced medical professionals.
Offers both surgical and non-surgical treatments.

PAIYY的劣势是什么？

Negative profit margin and P/E ratio.
Limited geographic presence.
Reliance on discretionary consumer spending.
Exposure to regulatory changes in the healthcare industry.

PAIYY有哪些机遇？

Expansion into new geographic markets.
Introduction of new aesthetic treatments and technologies.
Strategic partnerships and acquisitions.
Growing demand for aesthetic services in Asia.

PAIYY面临哪些威胁？

Intense competition from other aesthetic medical providers.
Economic downturns affecting consumer spending.
Changes in consumer preferences and beauty standards.
Regulatory risks and compliance requirements.

PAIYY的竞争对手是谁？

Beiersdorf AG — Global skincare and cosmetic company. — (BNVIF)
Encore Capital Group Inc — Debt recovery solutions provider (indirect competition for consumer spending). — (ECIA)
LAVA Therapeutics N.V. — Immuno-oncology company developing cancer therapies (different healthcare segment). — (LVVV)
Newpark Resources Inc — Provides products and services to the oil and gas industry (unrelated industry). — (NRPR)
Paktika Acquisition Corp. — Special purpose acquisition company (SPAC) - not a direct competitor but may invest in the space. — (PKTX)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Chen Zhang
Headquarters: Shenzhen, CN
Employees: 1,286
Founded: 2019

AI Insight

AI analysis pending for PAIYY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: PAIY

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aesthetic Medical International Holdings Group Limited do?

Aesthetic Medical International Holdings Group Limited operates as a provider of aesthetic medical services in China and Singapore. The company offers a range of surgical and non-surgical treatments, including eye surgery, rhinoplasty, laser therapies, and minimally invasive procedures. Additionally, it provides general healthcare services, such as internal medicine, gynecology, dermatology, and hair loss treatments. The company aims to provide comprehensive medical and aesthetic solutions to its customers through its clinics and medical facilities.

What do analysts say about PAIYY stock?

As of 2026-03-16, formal analyst ratings and price targets for PAIYY are unavailable, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and risk assessment. Key valuation metrics such as the negative P/E ratio suggest the company is currently unprofitable. Any investment decision should consider the company's growth potential, competitive landscape, and inherent risks associated with OTC-traded securities.

What are the main risks for PAIYY?

Investing in Aesthetic Medical International Holdings Group Limited carries several risks. The company's negative profit margin and P/E ratio indicate financial challenges. As an OTC-listed stock, PAIYY faces liquidity constraints and limited regulatory oversight. The aesthetic medical industry is highly competitive and subject to changing consumer preferences. Additionally, currency fluctuations and regulatory changes in China and Singapore could impact the company's performance. Investors should carefully consider these risks before investing.